Lithobid

— THERAPEUTIC CATEGORIES —
  • Mood disorders
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Lithobid Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Lithium carbonate 300mg; extended-release tabs.

    Pharmacological Class

    Lithium salt.

    How Supplied

    Tabs—100

    Manufacturer

    ANI Pharmaceuticals, Inc.

    Lithobid Indications

    Indications

    Mania in bipolar disorder.

    Lithobid Dosage and Administration

    Adult

    Swallow whole. Acute mania: 1800mg/day in 2–3 divided doses. Usual maintenance: 900–1200mg daily in 2–3 divided doses.

    Children

    Not recommended.

    Lithobid Contraindications

    Not Applicable

    Lithobid Boxed Warnings

    Boxed Warning

    Lithium toxicity.

    Lithobid Warnings/Precautions

    Warnings/Precautions

    Risk of lithium toxicity (esp. recent febrile illness, acute ingestion, volume depletion/dehydration, impaired renal function, cardiovascular disease, changes in electrolytes). Avoid in Brugada syndrome. Seizure disorders. Organic brain syndrome or other CNS impairment: monitor for neurologic toxicity. Dehydration. Maintain adequate fluid and salt intake esp. with fever, sweating, diarrhea, or infection. Monitor serum lithium levels frequently (toxic and therapeutic levels are close); draw blood for serum tests 8–12hrs after previous dose. Monitor thyroid, renal function, and for serotonin syndrome. Discontinue if diarrhea, vomiting, tremor, ataxia, drowsiness or weakness occur. Elderly. Pregnancy, nursing mothers: not recommended.

    Lithobid Pharmacokinetics

    See Literature

    Lithobid Interactions

    Interactions

    Lithium toxicity potentiated by diuretics, ACE inhibitors, angiotensin II receptor blockers, indomethacin, piroxicam (possibly other NSAIDs, including COX-2 inhibitors), metronidazole, calcium channel blockers: monitor and adjust lithium dose, if needed. Discontinue if signs of neurologic toxicity occur with antipsychotics. Xanthines, acetazolamide, urea, alkalinizing agents may reduce serum lithium levels. May potentiate adverse reactions of methyldopa, phenytoin, carbamazepine. Prolongs effects of neuromuscular blockers. Hypothyroidism with chronic iodide administration. Increased risk of serotonin syndrome with concomitant SSRIs, SNRIs, MAOIs; discontinue if occurs. Fluoxetine has variable effects on serum lithium levels. May be antagonized by SGLT2 inhibitors; monitor for frequently.

    Lithobid Adverse Reactions

    Adverse Reactions

    Polyuria, polydipsia, drowsiness, tremor, hypothyroidism, extrapyramidal symptoms, nausea, renal toxicity, seizures, arrhythmias, hypotension, lethargy, metallic taste, dry mouth, blurred vision, pseudotumor cerebri (discontinue if occurs), encephalopathic syndrome.

    Lithobid Clinical Trials

    See Literature

    Lithobid Note

    Not Applicable

    Lithobid Patient Counseling

    See Literature

    • Latest News Your top articles for Wednesday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More